Anti–Glycoprotein VI Treatment Severely Compromises Hemostasis in Mice With Reduced α ₂ β ₁ Levels or Concomitant Aspirin Therapy

Abstract

Anti-GP VI therapy may result in defective hemostasis in patients with reduced alpha2beta1 levels or concomitant aspirin therapy. These observations may have important implications for a potential use of anti-GP VI-based therapeutics in the prevention of cardiovascular disease.